A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo
about
Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrierHuman complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysisTargeted delivery of therapeutics to endothelium.Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.Targeting antioxidant and antithrombotic biotherapeutics to endothelium.Antibody targeting as a thrombolytic strategy.Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculatureAdvanced drug delivery systems for antithrombotic agents.Drug delivery by red blood cells: vascular carriers designed by mother nature.Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy.The Future of Nanoparticle-Directed Venous Therapy.Molecular biology and gene transfer in atherosclerosis in the stenting era.New antithrombotic strategies for resistant thrombotic processes.Targeting therapeutics to endothelium: are we there yet?Bifunctional fusion between nerve growth factor and a transferrin receptor antibody.Prourokinase-annexin V chimeras. Construction, expression, and characterization of recombinant proteins.
P2860
Q26801300-DD17E9D7-15B1-40E0-B8DB-3A72F4ED511AQ30444430-CDCA8EF4-6BEE-47E4-B69A-B1D45980FB64Q30475849-11111E05-5B4C-46EC-B1D8-B2917AC39DABQ33944248-E40C1E6E-251C-4FB8-82F7-6301C2DED345Q34935960-F41EA223-786C-44B4-BDC6-98A64AB9DF67Q35224543-325EB58F-3C26-4F8F-93AD-DD5750517E94Q35848131-5689CD63-49BA-4E38-B151-A062841BAD50Q36445835-F82D3119-E312-4EB1-B33E-AD8DC5626C81Q37132620-16760C92-D9C2-441E-8167-10654593D651Q37700751-A2A8B224-9FAE-4787-8DB3-D68D567EED83Q38527633-B6FBF485-B5AC-452A-A25F-782136D5ACF1Q38749932-E0580BBE-1A7D-405D-A604-CD9FE78E9318Q40601689-1967E257-E3AF-4E4F-84C9-6730BBEC4896Q40727618-62DB566F-BC50-46C9-A9EA-834E86FAD078Q47250590-9CE406C5-633D-4C0B-ADC1-12A923A6AF7FQ48055027-5E7C24E4-31B9-40E4-80F2-9E79310AB81BQ48070607-DB51DEE2-523A-4158-AF55-AB2119A52E96
P2860
A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
A recombinant chimeric plasmin ...... c potency in vitro and in vivo
@en
A recombinant chimeric plasmin ...... potency in vitro and in vivo.
@nl
type
label
A recombinant chimeric plasmin ...... c potency in vitro and in vivo
@en
A recombinant chimeric plasmin ...... potency in vitro and in vivo.
@nl
prefLabel
A recombinant chimeric plasmin ...... c potency in vitro and in vivo
@en
A recombinant chimeric plasmin ...... potency in vitro and in vivo.
@nl
P2093
P2860
P356
P1476
A recombinant chimeric plasmin ...... c potency in vitro and in vivo
@en
P2093
P J Zavodny
T Quertermous
P2860
P304
10337-10341
P356
10.1073/PNAS.88.22.10337
P407
P577
1991-11-01T00:00:00Z